Black Hawk Acquisition BKHA

Biotechnology, Healthcare

$5.40

+25.87%

Market cap: $22.4M
PE: n/m; one or more of the four quarters through 2026-08-31 missing
Forward PE: n/m; not a meaningful number
Price to sales: n/m; not a meaningful number
EV/EBIT: n/m; a loss over the last year
Revenue, 12 months: n/m; not a meaningful number
Net margin: n/m; not a meaningful number
Free cash flow yield: n/m; not a meaningful number

Charts

Financials

Income statement for BKHA, by quarter
Income statement	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
SG&A	$30.7K	$335.3K	$54.9K	$71.3K	$78.8K+157%	$217.6K−35%	$311.3K+467%	$187.9K+164%	$24.2K−69%	$79.2K−64%	$108.2K−65%
	−$30.7K	−$359.2K	−$84.9K	−$101.3K	−$108.8K+254%	−$247.6K−31%	−$341.3K+302%	−$217.9K+115%	−$54.2K−50%	−$109.2K−56%	−$138.2K−60%
Interest expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$19.4K	$24.4K	$33.2K
Net income	−$30.7K	$310.9K	$883.8K	$751.7K	$658.4K	$520.5K+67%	$154.4K−83%	−$3.8K	$139.8K−79%	$88.9K−83%	$1.1M+596%
	n/a	n/a	n/a	n/a	$0.07	$0.06	$0.03	n/a	$0.03−57%	$0.02−67%	$0.26+767%
	n/a	n/a	n/a	n/a	6.9M	6.9M	4.1M	n/a	2.1M−69%	2.1M−69%	2.1M−48%

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Black Hawk Acquisition's size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
BKHABlack Hawk Acquisition	$22.4M	n/m	n/a	n/m	n/m	n/m
NEPHNephros	$38.3M	22.1×	28.4×	1.9×	+24%	8.4%
ATNMActinium Pharmaceuticals	$47.8M	4.2×	3.1×	n/m	n/m	n/m
APTAlpha Pro Tech	$56.7M	13.6×	14.8×	0.9×	+6%	6.8%
SPROSpero Therapeutics	$64.6M	10.1×	9.5×	1.4×	−3%	15.7%
LFVNLifevantage	$73.4M	14.7×	19.6×	0.4×	−20%	2.8%
ICCCImmucell	$93.1M	128×	44.0×	3.0×	+8%	2.6%
KEQUKewaunee Scientific	$94.9M	11.9×	13.7×	0.3×	+5%	3.0%
PDEXPro DEX	$199.3M	15.1×	16.6×	2.6×	+16%	17.6%
PLXProtalix BioTherapeutics	$205.5M	11.1×	34.2×	2.5×	+30%	23.5%
NATRNatures Sunshine Products	$213.8M	12.0×	20.6×	0.4×	+7%	3.7%
Peer median	$83.3M	12.8×	18.1×	1.4×	+7%	6.8%